DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in Ka...
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Yahoo! Finance
– Up to US$184 million investment brings capital deployment to over US$1 billion since IPO – – Long-term asset in new therapeutic area further increases portfolio duration and diversification – TORONTO Nov. 4, 2024 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to US$179 million , comprised of a US$100 million upfront payment, up to US$57 million in a sales-based milestone payment and a one-time US$22 million optional payment. Additionally, the Trust is making a US$5 million investment in KalVista's common stock in a private placement transaction. If approved, sebetralstat would be the first and only oral on-demand therapy for treating attacks associated with hereditary angioedema ("HAE"). H
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.MarketBeat
- KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]Yahoo! Finance
- KalVista Appoints Jeb Ledell as Chief Operating OfficerBusiness Wire
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
KALV
Earnings
- 12/5/24 - Beat
KALV
Sec Filings
- 12/16/24 - Form 8-K
- 12/9/24 - Form 4
- 12/5/24 - Form 8-K
- KALV's page on the SEC website